Skip to main content

Table 3 MTD finding of ALT-803 in combination with M7824

From: Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer

Dose-Escalation Schedule

Dose Level

ALT-803

M7824

Level − 1

8 mcg/kg s.c.

1200 mg i.v.

Level 1

10 mcg/kg s.c.

1200 mg i.v.

Level 2

15 mcg/kg s.c.

1200 mg i.v.